IDH1 and central nervous system cancer: Isocitrate dehydrogenase 1 (IDH1) mutational status has been well recognized to be an important prognosis biomarker, and patients with IDH1 mutant gliomas commonly have a favorable prognosis compared with patients with wild-type (WT) IDH1 tumors (Noushmehr et al., 2010; Turcan et al., 2012; Eckel-Passow et al., 2015).